Nuclear orders are surging, margins must catch up
- Q1 2026 orders rose 42% including Paragon and Certrec, lifting backlog to a record $1.1 billion.
- Nuclear & Safety is now the main engine, with Q1 2026 revenue up 39% to $185.5 million.
- The Paragon deal is adding growth, but acquisition costs pulled Nuclear & Safety operating margin down to 11.3%.
- Medical is improving from a weak 2025, but management still calls the RTQA rebound early.
- The stock needs proof that orders turn into profitable revenue, not just a bigger backlog.
Orders are ahead of profits
Mirion looks better than its near-term profit numbers show. In Q1 2026, orders grew 19% organically and 42% including Paragon and Certrec, reaching $288 million. Backlog hit a record $1.1 billion. That is the clearest sign that demand from nuclear customers is speeding up.
The bull case is simple: nuclear power customers need trusted safety systems, monitoring tools, parts, and licensing support. Mirion now covers more of that chain after buying Paragon and Certrec. Paragon grew revenue 45% in its first quarter inside Mirion, and management says it is helping win more nuclear work, including small modular reactor, or SMR, projects.
The bear case is also clear. Growth from deals is not yet showing up cleanly in profit. Nuclear & Safety revenue grew 39% in Q1 2026, but segment operating income fell to $20.9 million and margin compressed to 11.3%. Mirion also has a more complex balance sheet after issuing $775 million of convertible notes in 2025, which can dilute shareholders later.
Finn's view should stay balanced. The growth score has real support from orders and backlog. The weaker performance, valuation, and financial health picture reflects the other side: investors still need evidence that Mirion can convert this nuclear demand into higher margins and cash flow.
Critical tools for regulated customers
Mirion makes money by selling radiation detection, measurement, monitoring, and safety systems. Its customers include nuclear power plants, defense agencies, research labs, hospitals, and cancer-care centers. These buyers care about safety, approvals, and reliability, so switching suppliers can be hard.
The business has two kinds of revenue. One is recurring flow work, such as replacements, service, dosimetry badges, and software tied to a large installed base. The other is larger project work, such as new plant systems, reactor upgrades, and SMR-related orders. The project work can be valuable, but the timing can move around.
Paragon and Certrec push Mirion deeper into the nuclear plant life cycle. Certrec helps with licensing and regulatory needs. Paragon helps with obsolescence, parts availability, and engineered solutions for large reactors and SMRs. That broader offer may help Mirion win more work, but it also raises the cost and risk of integration.
Medical gives the company a second lane. It sells quality assurance tools for radiation therapy, nuclear medicine equipment, dosimetry services, and newer AI software. This segment was a headwind in 2025, especially RTQA, so a lasting recovery would matter for both growth and margins.
Radiation tools across two markets
Nuclear detection and monitoring
These systems help nuclear sites detect, measure, and monitor radiation. Demand is rising as utilities extend plant lives and plan new reactor projects.
Paragon engineered nuclear solutions
Paragon adds safety-related systems, replacement parts, and obsolescence support. Management said Paragon revenue grew 45% in its first quarter inside Mirion.
Certrec regulatory compliance
Certrec helps nuclear customers with plant licensing and ongoing regulatory work. This makes Mirion more useful earlier in a plant's life cycle.
Defense and research instruments
Mirion sells radiation detection and identification tools to defense, labs, and research customers. This work adds breadth beyond commercial nuclear power.
Radiation Therapy Quality Assurance
RTQA products help make radiation cancer treatment safer and more accurate. The business was weak in 2025, but Q1 2026 commentary pointed to early hardware improvement.
Nuclear medicine and dosimetry
This area includes dose calibrators, nuclear medicine software, thyroid uptake systems, and personal radiation monitoring services. It supports hospitals and care teams that work around radiation.
AI and oncology software
The Oncospace acquisition added AI-focused radiation oncology software. It could improve Mirion's software mix, but AI also brings legal, compliance, and competitive risks.
Q1 mix shifted toward nuclear
Segment shares use Q1 2026 revenue from Mirion's Form 10-Q: Nuclear & Safety generated 72.0% of revenue and Medical generated 28.0%. The mix is now more concentrated in nuclear after Paragon and Certrec.
What can break the story
Deals add sales but not profit
High impact · Medium oddsParagon and Certrec are lifting revenue and orders, but Q1 2026 Nuclear & Safety operating margin fell to 11.3% from 16.3% a year earlier. Acquisition amortization and integration costs are the near-term drag. If synergies arrive slowly, the growth story may look expensive.
SMR orders take longer to convert
High impact · Medium oddsMirion's growth plan now depends in part on SMRs, which are small modular reactors that are still an emerging market. The company has order momentum, including a new $35 million SMR order won in April. But SMR customers still face design, regulatory, financing, and buildout risks.
Backlog stays lumpy
Medium impact · Medium oddsA record $1.1 billion backlog gives Mirion revenue visibility, but large nuclear projects do not always turn into revenue on a smooth schedule. Customer approvals, site work, and government decisions can push timing out. That can make quarterly results uneven even when demand is healthy.
Medical recovery stalls
Medium impact · Medium oddsMedical improved in Q1 2026, with revenue up 5.1% to $72.1 million and margin up to 10.8%. Still, management described RTQA improvement as early after a difficult 2025. If hardware demand in Japan or U.S. health care spending weakens again, a key margin helper could fade.
Convertible notes dilute owners
Medium impact · Medium oddsMirion issued $775 million of convertible notes in 2025. Convertible notes are debt that can later turn into stock under certain conditions. That can help fund growth today, but it can also dilute current shareholders if the share count rises.
Global politics hit projects
Medium impact · Low oddsMirion sells into global nuclear, defense, research, and medical markets. Trade limits, tariffs, currency swings, and geopolitical tension can change customer budgets or delay projects. The company has also flagged risks tied to Iran-related conflict and U.S.-China trade tension.
In one breath
What does Mirion Technologies do?
Mirion sells radiation detection, monitoring, measurement, and safety products. Its main customers are nuclear power plants, defense agencies, research labs, hospitals, and cancer-care providers.
Why is nuclear important to Mirion?
Nuclear & Safety made up 72.0% of Q1 2026 revenue. The segment is also where orders are growing fastest after the Paragon and Certrec acquisitions.
What is the biggest risk for Mirion stock?
The biggest risk is that strong orders do not turn into strong profit. Investors should watch whether Nuclear & Safety margins recover as Paragon and Certrec are integrated.
Is Mirion only a nuclear company?
No. Medical made up 28.0% of Q1 2026 revenue and includes radiation therapy quality assurance, nuclear medicine, dosimetry, and oncology software. Still, the company is now more tied to nuclear than before.